Patients with the following characteristics will be eligible for inclusion in the trial:
18 years or older at the time of inclusion
Diagnosis of Primary Open-Angle Glaucoma (POAG), Normal Tension-Glaucoma (NTG) or Pseudoexfoliation Glaucoma (PEXG) in one or both eyes diagnosticed by an ophthalmologist.
Best corrected Snellen VA of 0.3 or better in the study eye(s)
Two or more reliable VF tests with less than 15% false positives
You may not be if
Patients who meet any of the following criteria will be excluded from participation in the study:
Visual field damage worse than -16dB in the study eye(s)
Eye pressure greater than 35 mmHg in study eye(s) on either of two measurement occasions or a mean pressure of 30 mmHg over two occasions
Any disease affecting retinal function
Neurological or other non-glaucomatous conditions that may affect the visual field
Inability to perform visual field examination
Unwillingness to stop any intake of multivitamins or B vitamin substances
Known allergy or intolerance to B-vitamins
Previous eye surgery, except for uncomplicated cataract surgery
Pregnant or breastfeeding women
Women of childbearing potential who do not use reliable contraception
Any disease or condition likely to prevent long-term follow-up
Cancer diagnosis within the last 5 years (except treated squamous cell carcinoma)
History of liver disease or stomach ulcers
Inability to understand and speak Swedish or English
